Skip to main content
Fig. 1 | BMC Cancer

Fig. 1

From: REMARRY and PURSUIT trials: liquid biopsy-guided rechallenge with anti-epidermal growth factor receptor (EGFR) therapy with panitumumab plus irinotecan for patients with plasma RAS wild-type metastatic colorectal cancer

Fig. 1

Overall trial design. Liquid biopsies for OncoBEAM RAS CRC kit and/or Guardant360 will be performed in the PURSUIT trial at baseline, cycle 3, and after discontinuation of protocol treatment. C3: Cycle 3; G360: Guardant360; OncoBEAM: OncoBEAM RAS CRC kit; SOC: Standard of care. *Substitution of the result just before enrollment

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us